Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Steroidal compounds having a 17-(3-pyridyl) substituent together with a 16,17-double bond have been synthesized, using a palladium-catalyzed cross-coupling reaction of a 17-enol triflate with diethyl(3-pyridyl)borane, which are potent inhibitors of human testicular 17 alpha-hydroxylase-C17,20-lyase. The requirement for these structural features is stringent: compounds having 2-pyridyl (9), 4-pyridyl (10), or 2-pyridylmethyl (11) substituents instead of the 3-pyridyl substituent were either poor inhibitors or noninhibitory. Reduction of the 16,17-double bond to give 17 beta-pyridyl derivatives diminished potency with 3-pyridyl substitution (3-->27; IC50 for lyase, 2.9-->23 nM) but increased it with a 4-pyridyl substituent present (10-->28; IC50 1 microM-->53 nM). In contrast, a variety of substitution patterns in rings A-C of the steroid skeleton afforded inhibitors having potencies similar to those most closely related structurally to the natural substrates pregnenolone and progesterone, respectively 17-(3-pyridyl)androsta-5,16-dien-3 beta-ol (3, Kiapp < 1 nM; IC50 for lyase, 2.9 nM) and 17-(3-pyridyl)androsta-4,16-dien-3-one (15; IC50 for lyase, 2.1 nM). Thus compounds having variously aromatic ring A (18), saturated rings A/B (21, 22), and oxygenated ring C (26) exhibited IC50 values for lyase (1.8-3.0 nM) falling within a 2-fold range. The most potent compounds are candidates for development as drugs for the treatment of hormone-dependent prostatic carcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abiraterone acetate, a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17 (CYP17), a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [11]
Citations
Cites
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Palladium-catalyzed cross-coupling reaction of organoboron compounds with organic triflates
Ohe, T., Miyaura, N., & Suzuki, A. (1993) · The Journal of Organic Chemistry · doi:10.1021/jo00060a041 · Cited by 321
A method for the regiospecific synthesis of enol triflates by enolate trapping
Mc Murry, J. E., & Scott, W. J. (1983) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)81581-6 · Cited by 285
THE MECHANISM OF ENZYME-INHIBITOR-SUBSTRATE REACTIONS
Goldstein, A. (1944) · Journal of General Physiology · doi:10.1085/jgp.27.6.529 · Cited by 181
KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCER
Trachtenberg, J., & Pont, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92909-x · Cited by 162
Steroid Hormones: A Practical Approach
(1989) · Tumori Journal · doi:10.1177/030089168907500230 · Cited by 100
Labrie, F., Belanger, A., Simard, J., Labrie, C., & Dupont, A. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6 · Cited by 94
Is there a case for P-450 inhibitors in cancer treatment?
Wauwe, J. P. V., & Janssen, P. A. J. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00130a001 · Cited by 88
FORTI, G., SALERNO, R., MONETI, G., ZOPPI, S., FIORELLI, G., MARINONI, T., NATALI, A., COSTANTINI, A., SERIO, M., MARTINI, L., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-461 · Cited by 83
Cited by
Items 301–400 of 403
Sodium Bis(2-methoxyethoxy)aluminum Hydride
Gugelchuk, M., Silva, L. F., Vasconcelos, R. S., & Quintiliano, S. A. P. (2007) · Encyclopedia of Reagents for Organic Synthesis · doi:10.1002/9780470842898.rs049.pub2 · Cited by 4
Pyridine C─N Transposition via Cycloaddition–Cycloreversion
Conboy, A., & Greaney, M. F. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.5249878 · Cited by 3
Acétate d’abiratérone (AA) : comment prescrire l’abiratérone et à qui en 2014 ?
Boissier, É., Loriot, Y., Vignot, S., & Massard, C. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.1932 · Cited by 3
Rao, S. N., & Habra, M. A. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0247-9 · Cited by 3
Androgen Receptor in Health and Disease
Marcelli, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-46086-4_2 · Cited by 3
The role of abiraterone in the management of metastatic castration-resistant prostate cancer
Rawlinson, A., Mohammed, A. A., Beatty, J. D., Bell, R., & Miller, M. A. W. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.12 · Cited by 3
Li, Y., Liu, J., Wang, L., Qing, X., & Wang, C. (2016) · Steroids · doi:10.1016/j.steroids.2016.05.004 · Cited by 3
In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1
Kędzierski, J., Jäger, M.-C., Naeem, S., Odermatt, A., & Smieško, M. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116945 · Cited by 3
Hayama, N., Horiyama, S., Okamoto, R., Nishi, Y., Yada, M., Higashida, R., Haginaka, J., & Usami, Y. (2025) · ChemBioChem · doi:10.1002/cbic.202500675 · Cited by 2
Pyridine C─N Transposition via Cycloaddition–Cycloreversion
Conboy, A., & Greaney, M. F. (2026) · Angewandte Chemie · doi:10.1002/ange.5249878 · Cited by 2
Dupuy, L., Long, J., & Ranchoup, Y. (2013) · Case Reports in Oncology · doi:10.1159/000353131 · Cited by 2
Abiraterone for the Treatment of mCRPC
Zafeiriou, Z., Mehra, N., & Bono, J. S. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-31341-2_9 · Cited by 2
Development of Enzyme Inhibitors as Drugs
Smith, H. J., & Simons, C. (2004) · CRC Press eBooks · doi:10.1201/9780203414583-11 · Cited by 2
Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer
Barata, P. C., Layton, J. L., Lewis, B. E., & Sartor, O. A. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000428 · Cited by 2
Latysheva, А. S., Zolottsev, V. А., Veselovsky, A. V., Scherbakov, K. A., Morozevich, G. E., Zhdanov, D. D., Новиков, Р. А., & Misharin, A. Y. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106280 · Cited by 2
Kastrationsrefraktäres Prostatakarzinom (CRPC)
Loidl, W. C., Luger, F., & Roosen, A. (2014) · Der Urologe · doi:10.1007/s00120-013-3377-0 · Cited by 2
Azadiradione Analogs from 13α- and 13β-Dehydro-epi-androsterone
Fernández-Mateos, A., Moreno, C. M., González, R. R., & HERNANDEZ, C. T. (1998) · Journal of Chemical Research Synopses · doi:10.1039/a807130f · Cited by 2
Essential oil terpenes may inhibit steroidogenic cytochrome P450 activitiesPreprint
Sharma, K., Lanzilotto, A., Yakubu, J., Therkelsen, S., Voegel, C. D., du Toit, T., Jørgensen, F. S., & Pandey, A. V. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.31.564977 · Cited by 2
Androgen Receptor in Health and Disease
Hohl, A., & Marcelli, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_2 · Cited by 2
Jiao, Y., Ho, I., Li, T., Na, R., Wong, C., Wang, J., Siu, S. W. K., Wei, Y., Chen, Y., Chan, E. W., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112249 · Cited by 1
Quality by Design Driven Improved Process of Abiraterone Acetate
Ratnamala, A., Bandichhor, R., Annapurna, S. C. V., Rao, S. T., Bathini, P. K., Gaddameedhi, P. R., Komati, S. K., Manda, A., Nahide, P. D., Reddy, B. R., et al. (2025) · Synthesis · doi:10.1055/s-0043-1775476 · Cited by 1
Grudzińska, A., Yakubu, J., Vigato, C., du Toit, T., Vanzetti, G., Zan, R., Boschi, D., Oliaro‐Bosso, S., Björkling, F., Jørgensen, F. S., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70336 · Cited by 1
Aggarwal, R. R., & Ryan, C. J. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.10.006 · Cited by 1
Stratégie de prise en charge des cancers de la prostate réfractaires à la castration
Gross‐Goupil, M., Roca, S., Pasticier, G., & Ravaud, A. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1562 · Cited by 1
Hsiao, J. J., Smits, M. M., Ng, B. H., Lee, J., & Wright, M. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-01554-2 · Cited by 1
Development of Enzyme Inhibitors as Drugs
Smith, H. J., & Simons, C. (2004) · CRC Press eBooks · doi:10.1201/9780203414583.ch5 · Cited by 1
Soylu, H., Aksu, K., Üstünel, İ., Karaçor, K., & Beyazçiçek, Ö. (2023) · Sağlık Bilimlerinde Değer · doi:10.33631/sabd.1125407 · Cited by 1
Ramezani, S. R., Mojra, A., & Tafazzoli‐Shadpour, M. (2024) · National and International Iranian Conference on Biomedical Engineering (ICBME) · doi:10.1109/icbme64381.2024.10895809 · Cited by 2
Molecular Targeted Therapies of Prostate Cancer
Vlachostergios, P. J., Paddock, M. N., & Molina, A. M. (2017) · Molecular pathology library · doi:10.1007/978-3-319-64096-9_29 · Cited by 1
Ogita, S., LoRusso, P. M., & Li, J. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm132 · Cited by 1
Yang, Y. C. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0165748 · Cited by 1
Belfort, G. M., Harrison, B. L., & Botella, G. M. (2016) · Wiley eBooks · doi:10.1002/9783527800315.ch6 · Cited by 1
Androgen Receptor Pathway in Prostate Cancer: Old Target and New Drugs
Massard, C., & Fizazi, K. S. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1764-4_13 · Cited by 1
Prodrugs: Strategic Deployment, Metabolic Considerations, and Chemical Design Principles
Erhardt, P., Khupse, R. S., Sarver, J. G., & Kress, B. J. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc157.pub2 · Cited by 1
Functionalization of Pyridines at Remote Synthetic Landscapes via Undirected Metalation and CapturePreprint
Hsu, H.-H., Chen, C., Kang, S., Sk, M. R., & Thomas, A. A. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-g6nk9 · Cited by 1
Hu, Q. (2010) · Publications of the UdS (Saarland University) · doi:10.22028/d291-22685
Hormone Blocking Anticancer Drugs
(2015) · Wiley eBooks · doi:10.1002/9781118892572.ch3
New Therapies in Hormone Relapsed Disease
Pezaro, C. J., Omlin, A. G., Bianchini, D., & Bono, J. S. D. (2014) · Wiley eBooks · doi:10.1002/9781118347379.ch14
New Treatment Developments Applied to Elderly Patients
Mukherji, D., Pezaro, C. J., & Bono, J. S. D. (2012) · Springer eBooks · doi:10.1007/978-0-85729-999-4_15
Cancer de la prostate : mise au point 2014
Delongchamps, N. B. (2014) · Journal de radiologie diagnostique et interventionnelle · doi:10.1016/j.jradio.2014.04.006
Abiraterone Acetate for the Treatment of Castrate-Refractory Prostate Cancer
Caley, A., & Staffurth, J. N. (2013) · Aging Health · doi:10.2217/ahe.12.76
Abiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel
Poppel, H. V., Osanto, S., & Joniau, S. (2012) · Clinical Investigation · doi:10.4155/cli.12.100
Jarman, M. (1996) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.5.2.245
Self-citationPrezioso, D. (2013) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.s5-001
Resisting resistance: Establishing new treatment options for CRPC patients
Beedie, S., & Figg, W. D. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139271
Biersack, B. (2009) · EPub Bayreuth (University of Bayreuth)
Crystal structure of 3β-acetoxyandrosta-5,16-dien-17-yl trifluoromethanesulfonate
Zhou, S., Huang, H.-Q., Zhang, T., Wang, D., & Huang, R. (2015) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989015009123
Martínez-Hernández, L., Martínez-Prieto, M., & Galván-Salazar, G. (2016)
Sidiropoulos, C. C. (2015) · Hellenic Urology · doi:10.19264/hj.v26i4.45
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2017) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub3
Dellavedova, T., Reynoso, E. M., Quinteros, L., Raul, N., Ponzano, R., Sarria, J. P., Olmedo, J., & Minuzzi, F. (2017) · Clinical Case Reports and Reviews · doi:10.15761/ccrr.1000318
Nickel-Catalysed Synthesis of 17-Arylandrosta-5,16-Dienes
Wang, L., Wang, T., Dai, C., Li, Y., & Wang, C. (2017) · Journal of Chemical Research · doi:10.3184/174751917x15094552081206
Castration-Resistant Prostate Cancer
Davies, A., Bishop, J. L., & Zoubeidi, A. (2017) · Molecular pathology library · doi:10.1007/978-3-319-64096-9_18
Investigating the role of amino acid transporter LAT3/SLC43A1 in prostate cancer
Zhang, K. (2019) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 1
Iwata, M., 健一郎, 堤., & 寧, 原. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.145.260
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2022) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub4
(2008) · Springer eBooks · doi:10.1007/3-540-30439-8_36
Sodium Bis(2-methoxyethoxy)aluminum Hydride
Gugelchuk, M., Silva, L. F., Vasconcelos, R. S., & Quintiliano, S. A. P. (2007) · Encyclopedia of Reagents for Organic Synthesis · doi:10.1002/047084289x.rs049.pub2
Ferreira, A. R., Abrunhosa-Branquinho, A. N., Vendrell, I., Quintela, A., Pina, F., & Ribeiro, L. (2015) · Springer eBooks · doi:10.1007/978-3-319-21683-6_22
Pais, H. L., Ulrich, J., & Ribeiro, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-16245-0_26
Synthesis and characterization of epoxide impurities of abiraterone acetate
Shirazi, S. M. H., Mokhtari, J., & Mirjafary, Z. (2022) · Steroids · doi:10.1016/j.steroids.2022.108988
Synthesis and Characterization of API‐Related Substances in Abiraterone Acetate**
Sasikala, C. V. A., Namshamgari, S., Bandreddi, V., Nahide, P. D., Kumar, C. K., Roy, A. K., Vakamulla, M., Madhra, M. K., Ratnamala, A., & Bandichhor, R. (2023) · ChemistrySelect · doi:10.1002/slct.202204822
Steroidal 21-Imidazolium Salt Derivatives: Synthesis and Antitumoral ActivityPreprint
Sucman, N. S., Bilan, D. Y., Cojocari, S., Pogrebnoi, V., Stingaci, E., Khripach, V. A., Zhabinskii, V. N., Tsybruk, T. V., Grabovec, I. P., Panibrat, O. V., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4825103
New Nitrogen-containing Androstane Derivatives Suppressing Prostate Carcinoma Cells Proliferation
Latysheva, А. S., Misharin, A. Y., Veselovsky, A. V., Morozevich, G. E., Новиков, Р. А., & Zolottsev, V. А. (2024) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00241
Androgenrezeptor in Gesundheit und Krankheit
Hohl, A., & Marcelli, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_2
Total synthetic studies on potent compounds as anti-prostate cancer agents
Javan, M. J., & Youseftabar‐Miri, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21842-2.00012-7
Androgen biosynthesis suppressors in prostate cancer therapy
Chen, Q. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23585-6.00007-8
Hamstra, D. A., Dignam, J. J., Bruner, D. W., Michaelson, M. D., Bachand, F., Master, V. A., Torres, M. A., Saylor, P. J., Wallace, R. E., Vapiwala, N., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.07.1425
Korolchuk, A. M., Reshmina, O. Y., Misharin, A. Y., & Zolottsev, V. А. (2025) · Russian Journal of Oncology · doi:10.17816/onco692371
Chan, H.-Y., Huang, P.-S., Chiu, P.-F., Lin, T.-S., Huang, L.-J., Liang, P., Guh, J., & Lin, M.-H. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130515
Ho, T. M., & Yoshimoto, F. K. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00954e
Impact of CYP17A1 Gene Polymorphisms on Abiraterone Efficacy in Prostate Cancer: A Systematic Review
Sidibe, M., Tazzite, A., Jouhadi, H., & Dehbi, H. (2025) · Journal of Current Oncology · doi:10.1177/25898892251410395
Development of new approaches for the synthesis of flavaglines
Basmadjian, C. (2015) · theses.fr (ABES) · doi:10.70675/7d68b550za64ez450ez9652z105c70164939
Synthesis and cytotoxicity evaluation of steroidal 17β-hydroxy-17α-methylisoxazoles
Krech, A., Aleksandrova, A., Mekhtiev, A., Timoshenko, O., Kugaevskaya, E. V., Zavialova, M. G., Scherbakov, K. A., Chernysheva, A., Sorokin, D. V., Scherbakov, A. M., et al. (2026) · Steroids · doi:10.1016/j.steroids.2026.109807
La, J., Wang, L., Corrigan, J. K., Lang, D., Do, N., Brophy, M. T., Fillmore, N. R., & Paller, C. J. (2026) · JCO Clinical Cancer Informatics · doi:10.1200/cci-25-00213 · Cited by 1
Positional isomerization of pyridine through nitrogen transposition
Choi, W., 주혜원, Park, J., & Hong, S. (2026) · Nature · doi:10.1038/s41586-026-11006-4
Fortunato, G. C., Duarte, J. L., Luiz, M. T., & Chorilli, M. (2026) · Therapeutic Delivery · doi:10.1080/20415990.2026.2742645
BindingDB Entry 50043023: Synthetic approaches to the 2011 new drugs.
BindingDB (2014) · UC San Diego · doi:10.7270/q2dv1m8c
BindingDB (2010) · UC San Diego · doi:10.7270/q2222tk7
Metadata
- Authors
- Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Jarman, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-06
- Volume
- 38
- Issue
- 13
- Pages
- 2463-2471
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2027081726
- Cited by
- 379
- References
- 33
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 21 · 2016: 20 · 2015: 21 · 2014: 28 · 2013: 31 · 2012: 28
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Keywords
- CYP17 inhibitors, steroids, palladium-catalyzed cross-coupling, structure-activity relationship, steroid synthesis, prostate cancer, hormone-dependent prostate cancer, androstenedione, pregnenolone, progesterone
- MeSH terms
- Humans, Male, Magnetic Resonance Spectroscopy, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Steroids, Structure-Activity Relationship, Testis, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.